UMCG Defends Delay in Informing Brain Tumor Patients of Proton Therapy Risks

The University Medical centre Groningen (UMCG) has defended its decision to delay informing patients about potential risks associated with proton therapy for brain tumors. The hospital stated it did not want to cause “unnecessary worry” among those undergoing treatment.

Delayed Disclosure of Research Findings

This response comes following reports from NRC and Follow the Money detailing the experience of Wouter Slegt, a patient who began proton therapy for a grade 3 glioblastoma at the UMCG last year. An investigation completed in July revealed a significantly elevated risk for patients receiving proton therapy for this specific type of brain tumor.

Increased Risk of Mortality

The research, conducted across three proton centres including the UMCG, indicated that patients with grade 3 glioblastomas treated with proton therapy faced a five times greater risk of death compared to those receiving conventional treatment methods. Despite this finding, the UMCG continued treatment for Slegt until July 18th, two weeks after the decision to temporarily halt the therapy was made.

Did You Know? Approximately one hundred patients had received proton therapy at the UMCG in recent years before the findings regarding grade 3 glioblastomas were disclosed.

The results of the investigation were not shared with patients until November, as reported by NRC. The hospital explained that it prioritized verifying the accuracy of the data before communicating it to patients.

Continued Use of Proton Therapy

The UMCG maintains that proton therapy remains an “recognized and safe treatment.” While treatment has been suspended for patients with grade 3 glioblastomas, the hospital intends to continue offering proton therapy for other conditions.

Expert Insight: The decision to withhold preliminary research findings, even with the intention of ensuring accuracy, highlights the complex ethical considerations inherent in medical research and patient care. Balancing the potential for causing anxiety with the patient’s right to informed consent is a critical challenge for healthcare institutions.

The UMCG encourages patients with concerns to contact their treating physician.

Frequently Asked Questions

What type of tumor was the focus of the research?

The research focused on patients with a grade 3 glioblastoma, a type of brain tumor.

When did the UMCG stop treating grade 3 glioblastoma patients with proton therapy?

The UMCG stopped the proton therapy for patients with a grade 3 glioblastoma after a decision made in the first week of July.

When were patients informed about the research findings?

Approximately one hundred patients who had received proton therapy in the past were informed in November.

How do you weigh the benefits of potentially life-saving treatments against the importance of immediate transparency regarding emerging risks?